Cutaneous mucormycosis is an emerging fungal infection caused by opportunistic
fungi of the phylum Glomeromycota. It is frequent in poorly controlled diabetic
patients and individuals with immunosuppression. It is usually acquired by
direct inoculation through trauma. The clinical presentation is nonspecific, but
an indurated plaque that rapidly evolves to necrosis is a common finding.
Diagnosis should be confirmed by demonstration of the etiological agent and new
molecular diagnostic tools have recently been described. It is an invasive
life-threatening disease and in order to improve survival, a prompt diagnosis
and multidisciplinary management should be provided. The treatment of choice is
amphotericin B, but new azoles, such as posaconazole and isavuconazole, must be
considered.
Our results support the recommendation for assessing insulin resistance and cardiovascular-related features and disorders in all young males with stage III or higher AGA, according to the Hamilton-Norwood classification.
Ecthyma gangrenosum is a rare skin infection classically associated with
Pseudomonas aeruginosa. We performed a retrospective study of all cases
diagnosed with ecthyma gangrenosum from 2004-2010 in a university hospital in
Mexico (8 cases, 5 female patients and 3 male patients, ages between 4 months
and 2 years). The most common risk factor for ecthyma gangrenosum is neutropenia
in immunocompromised patients. In previously healthy patients, immunological
evaluation is important to rule out underlying immunodeficiency. Ecthyma
gangrenosum in healthy patients has a high mortality rate and early diagnosis
and aggressive antibiotic treatment is imperative as it can improve patients'
prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.